封面图片
2022年, 第16卷 第3期
Abivertinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, could inhibit MK differentiation and platelet biogenesis and might be an agent for thrombocythemia. (Courtesy of Dr. Jie Jin. See pages 416-428 by Jiansong Huang et al. for more information.)